985 / 1674
Endpoints
46
Primary Endpoint:
LR in ipsilateral breast
Secondary Endpoints
•
Normal tissue effects assessed by:
•
Physicians (at 1, 2, 5 & 10 years)
•
Patients (EORTC QLQ-C30, BR23, HADS, EQ5D at
baseline, 6 months, 1, 2 & 5 years)
•
Photographs (at baseline, 2 & 5 years)
•
Contralateral breast tumour
•
Regional & distant metastases